Various options and decision-making tools exist, some old, some novel. Traditional decision making based on, for example, price referencing, DRGs budgets or generic substitution are still significant. However, recent advances in the sophistication of HTA analysis and modeling, flexible pay for performance models, risk-sharing and value-based pricing schemes have become increasingly important to mitigate payer risk and allocate financial resources to the areas of pressing need. Savings and outcome improvements can also be found through finding efficiency gains at the healthcare delivery level, providing the right incentives for prescribers and improving patient adherence. 3 EVENTS IN ONE: 1. International Pharmaceutical Payers & HTA Summit 2. Among Action: Experiences With the German Pharmaceutical Pricing & Reimbursement Reform 3. Market Access for High Value Speciality & Biologic Medicines Request agenda at http://bigdata2014.nextlevelpharma.com/request-agenda .